184 related articles for article (PubMed ID: 33439464)
1. Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of
Happel C; Kranert WT; Gröner D; Baumgarten J; Halstenberg J; Bockisch B; Sabet A; Grünwald F
Endocrine; 2021 Jul; 73(1):125-130. PubMed ID: 33439464
[TBL] [Abstract][Full Text] [Related]
2. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
3. The influence of thyroid hormone medication on intra-therapeutic half-life of
Happel C; Kranert WT; Bockisch B; Sabet A; Grünwald F; Groener D
Sci Rep; 2022 Aug; 12(1):13925. PubMed ID: 35978004
[TBL] [Abstract][Full Text] [Related]
4. The influence of thionamides on intra-thyroidal uptake of
Happel C; Bockisch B; Leonhäuser B; Sabet A; Grünwald F; Groener D
Sci Rep; 2023 Dec; 13(1):21190. PubMed ID: 38040820
[TBL] [Abstract][Full Text] [Related]
5. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
[TBL] [Abstract][Full Text] [Related]
6. Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.
Happel C; Kranert WT; Ackermann H; Binse I; Bockisch B; Gröner D; Herrmann K; Grünwald F
Endocrine; 2019 Mar; 63(3):537-544. PubMed ID: 30599051
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?
Dederichs B; Dietlein M; Jenniches-Kloth B; Schmidt M; Theissen P; Moka D; Schicha H
Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):366-70. PubMed ID: 16915539
[TBL] [Abstract][Full Text] [Related]
8. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
9. Strategies of radioiodine therapy for Graves' disease.
Lind P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
[TBL] [Abstract][Full Text] [Related]
10. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
12. Graves' ophthalmopathy in patients treated with radioiodine 131-I.
Bałdys-Waligórska A; Gołkowski F; Kusnierz-Cabala B; Buziak-Bereza M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(3):214-9. PubMed ID: 21717402
[TBL] [Abstract][Full Text] [Related]
13.
Zhao L; Zhang W; Xin Y; Wen Q; Bail L; Guan F; Bin J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):349-353. PubMed ID: 30413358
[TBL] [Abstract][Full Text] [Related]
14. Effect of Lugol's solution on
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Clin Exp Med; 2023 Jul; 23(3):825-831. PubMed ID: 35840869
[TBL] [Abstract][Full Text] [Related]
15. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
Zantut-Wittmann DE; Ramos CD; Santos AO; Lima MM; Panzan AD; Facuri FV; Etchebehere EC; Lima MC; Tambascia MA; Camargo EE
Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
[TBL] [Abstract][Full Text] [Related]
16. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
17. Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?
Dunkelmann S; Künstner H; Nabavi E; Eberlein U; Groth P; Schümichen C
Nuklearmedizin; 2006; 45(5):213-8; quiz N51-2. PubMed ID: 17043732
[TBL] [Abstract][Full Text] [Related]
18. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
19. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine therapy and Graves' disease - Myths and reality.
Plazinska MT; Sawicka-Gutaj N; Czarnywojtek A; Wolinski K; Kobylecka M; Karlińska M; Prasek K; Zgorzalewicz-Stachowiak M; Borowska M; Gut P; Ruchala M; Krolicki L
PLoS One; 2020; 15(1):e0226495. PubMed ID: 31929534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]